Searchable abstracts of presentations at key conferences in endocrinology

ea0011p617 | Neuroendocrinology and behaviour | ECE2006

The levels of ghrelin and leptin and body fat mass in patients treated for thyroid dysfunction

Brunova J , Karasova L , Kasalicky P

Introduction: Patients successfully treated for hyperthyroidism show often the excessive weight gain and patients with hypothyroidism seldom regain their premorbid weight despite satisfactory control of their thyroid function.Aim of study: We compared the levels of hormones of ghrelin and leptin in patients with hyper and hypothyroidism, treated and untreated. We aimed to find if they play a role in a new energy balance in these patients.<p class="ab...

ea0008p80 | Reproduction | SFE2004

Arterial viscoelastic properties and blood pressure in pregnant women with polycystic ovary syndrome

Hu S , Seifalian AM , Hardiman P

Objective: We previously reported that the reduced arterial elasticity in polycystic ovary syndrome (PCOS) women is present in the first trimester of pregnancy. Women with reduced arterial elasticity are more likely to develop pre eclampsia, which association with PCOS is still unproven. This study was designed to compare blood pressure (BP) and arterial elasticity in pregnant PCOS women and controls in second trimester.Methods: The subjects were 15 preg...

ea0003p247 | Steroids | BES2002

The prevalence and morbidity of long-term oral corticosteroid therapy

Mackie J , Cooper M , Stewart P

Background: The adverse effects of corticosteroid therapy are similar to those of endogenous glucocorticoid excess. Previous studies have established the usage patterns of oral corticosteroids in the primary healthcare setting, but these have concentrated on corticosteroid-induced osteoporosis. The aim of this study was to investigate the prevalence and morbidity of long-term oral corticosteroids in a General Practice setting.Methods: From a population ...

ea0002p92 | Steroids | SFE2001

MODULATION OF CORTISOL METABOLISM DURING TREATMENT OF ACROMEGALY IS INDEPENDENT OF BODY COMPOSITION AND INSULIN SENSITIVITY

Monson J , Jenkins P , Taylor N , Yeo P , Carroll P , Camacho-Hubner C , Noonan K , Perry L , Besser G

Cortisol metabolism is modulated by inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1) during GH replacement (Weaver et al, Clin Endocrinol, 1994, 41, 639; Gelding et al, Clin Endocrinol, 1998, 48, 153) and in active acromegaly (Moore et al, J Clin Endocrinol Metab, 1999, 84, 4172). 11 beta HSD1 activity is also influenced by both fat mass and insulin. To determine the relative contribution of GH/IGF-I to alteration in cortisol metabolism we have examined...

ea0010oc8 | Reproduction, neuroendocrinology and diabetes | SFE2005

Twice-daily biphasic insulin aspart 30 plus metformin compared with once-daily insulin glargine in combination with glimepiride in type 2 diabetes

Kann P , Regulski|J##Medding M

In patients failing on oral antidiabetic (OAD) medication, insulin therapy is frequently started by adding basal or premixed insulin preparations to existing OADs. The aim of the study was to compare the efficacy and safety of two insulin analogue regimens in 255 patients (131 male; mean±SD age, 61.2±9.1 yrs) with type 2 diabetes. All patients gave written, informed consent; the study was approved by a local Ethical Committee and was performed in accordance with the ...

ea0026p83 | Endocrine tumours and neoplasia | ECE2011

Effectiveness of zolendronic acid yearly for preventing bone loss in patients with neuroendocrine tumors on somatostatin analogue therapy

Zdunowski P , Misiorowski W , Zgliczynski W

Background: Neuroendocrine tumors awareness is developing. Carcinoid syndrome and hormonal overproduction may be controlled with somatostatin analogues in majority of cases. However, due to unspecific symptomatology in early stages of disease, majority of cases are diagnosed when process is disseminated. Co-morbidities and coexisting diseases are present in most of patients. Bone loss may be accelerated by metastizing tumor, peptides secreted or decreased absorption of vitamin...

ea0019p130 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Withdrawal of proton-pump inhibitor (PPI) therapy in chronically hypomagnesaemic patients

Mackay J , Choudary N , Bladon P

We studied 5 female patients, aged 54–79 years old (mean 70.6 years), on PPI therapy for 2–13 years (mean 8.2 years), who were symptomatic from chronic and sometimes severe hypomagnesaemia (lowest readings 0.36, 0.29, & <0.21 mmol/l in 3 patients) for 7–45 months (mean 29.2 months). Oral magnesium (Mg) supplements were either poorly tolerated or ineffective; and repeated magnesium sulphate infusions (total doses per patient 120–1200 mmol Mg, mean 44...

ea0010p84 | Steroids to include Cushing's | SFE2005

Comparison of salivary and serum cortisol values during hydrocortisone day curves in hypocortisolaemic patients

Anthonypillai F , McEwen A , Hucklebridge F , Evans P

ObjectiveTo investigate whether salivary cortisol could provide an alternative to serum cortisol for hypocortisolaemic patients undergoing hydrocortisone day curves.MethodCorrelational study of 58 patients receiving corticosteroid replacement therapy for primary (9) or secondary (49) hypocortisolaemia. Paired samples of saliva and serum were taken at pre-determined time points throughout a 7½ hour hydroc...

ea0006oc29 | Neuroendocrinology | SFE2003

EFFICACY AND SAFETY OF TITRATED-DOSES LANREOTIDE AUTOGEL IN PATIENTS WITH ACROMEGALY

Jenkins P , #Lanreotide|#Autogel|#Study|#Group|#

Introduction: Lanreotide Autogel(R) is a long-acting somatostatin analogue preparation that is presented in pre-filled syringes for deep subcutaneous (sc) injection. The efficacy and tolerability of lanreotide Autogel given in titrated doses (ATG-TITRATE) for the treatment of acromegaly was assessed during this study.Methods: The study extended an existing study, during which fixed doses of lanreotide Autogel (ATG-FIX, 60, 90 and 120 mg) were ...

ea0003p106 | Diabetes &amp; Metabolism | BES2002

Audit on lipid management in diabetes

Moulik P , Nethaji C , Arsalanizadeh B , Khaleeli A

Background and aims: Cardiovascular (CVS) disease accounts for the majority of morbidity and mortality in diabetes. We audited lipid management in a hospital diabetes clinic.Patients: CVS disease risk factors were assessed in 241 consecutive patients with diabetes (type1 15%, type2 85%, male 53%, female 47%, mean age 59±13 years, mean duration of diabetes 10±9 years). 86(36%) had symptomatic atherosclerotic vascular disease (secondary prev...